Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Martin Vlcek is a full-time investor and analyst who has been actively investing and managing money for more than 15 years. Martin has an Economics degree. He currently works for an asset management company BH Securities. Ideas and information expressed in his articles on SeekingAlpha are his own and don't represent an official BH Securities opinion. Martin’s investment philosophy is to hold a truly diversified portfolio of investments across asset classes with low or negative correlation and a positive carry if possible. His primary stock investment focus is on undervalued stocks with upcoming catalysts and a favorable reward-to-risk ratio.
Martin became a full-time investor and money manager after a 15-year career in online marketing where he was one of the pioneers of the pay-per-click search. Martin later held managerial positions at several Fortune 500 companies and also managed his own startup company.
IMPORTANT DISCLAIMER: Martin is not a Registered Investment Advisor, Broker/Dealer, Securities Broker or Financial Planner. The Information in his articles, his comment and his premium subscription service on SeekingAlpha.com or elsewhere is provided for information purposes only. The Information is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any individual. Before using Martin's information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence. None of the information provided by Martin is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. Martin is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.
At Bio Vantage, our mission is to provide high-quality equity reports focused primarily on biotech and pharmaceutical companies worldwide. In our view, fundamental analysis of biopharmaceutical companies requires expertise in evaluating clinical trial data and drug pipelines, as these events often drive the underlying equity value of such companies going forward. Equally important is the ability to forecast future revenues, earnings growth, and cash flows using financial modeling tools in order to derive an intrinsic value for the company being analyzed. Once a fundamental value is derived, investors can make profits from a variety of trading instruments.
While our expertise largely concerns biotech and pharmaceutical companies, our investment principles are centered on diversification, asset allocation, risk management, and portfolio strategies. Thus, our investments and analyses also cover other sectors, including technology, financials, consumer products, energy, and commodities.
Bio Vantage's analysts have extensive experience in the biomedical field and in drug discovery research. We are lifelong investors. One of the analysts holds the CFA charter designation.
Jennifer Lynn is a proficient investor, executive and manager working with analytics data to drive smart business decisions. Technology, eCommerce, Management, Healthcare, Consulting, Strategy. Passionate for Finance, IT & Emerging Markets.
Email: consultbydigital @ gmail.com